Quantum BioPharma

Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.

Phase 1 complete. IND submitted for Phase 2 trial design.

Lucid-MS is investigational and not approved by FDA or Health Canada.

Sign up for email alerts : https://quantumbiopharma.com/email-alerts


$QNTM

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in the latest episode of The BioMedWire Podcast, with Anthony Durkacz, Co-Founder and Executive Co-Chair, discussing the company’s Lucid-MS development program, unbuzzd™ commercial strategy, and key milestones ahead for 2026.

The conversation highlights Quantum BioPharma’s focus on multiple sclerosis research, demyelination, neurodegenerative disease, and the broader strategy behind its biotech and commercial asset portfolio.

Watch the full episode here:
https://www.youtube.com/watch?v=clA0PZNfY1A

Lucid-MS is an investigational drug candidate. It is not approved by the FDA, Health Canada, or any other regulatory authority. This post is for informational purposes only and does not constitute medical advice, investment advice, or a recommendation to buy or sell securities.

Quantum BioPharma $QNTM: Lucid-MS, unbuzzd™ & 2026 Milestones | BioMedWire Podcast Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPh...